Because NUP214 is part of the nuclear pore complex and is a critical player in the nuclear export of proteins and mRNA, several inhibitors of nuclear export proteins, such as CRM1 and XPO1, may have potential therapeutic effects in patients with AML and DEK-NUP214 fusion.[38,39]. This evidence concerns the gene XPO1 and acute myeloid leukemia.